Skip to content
Menu

Lantern Pharma Inc. LTRN

Full chart Compare
Set alert

Price alert · LTRN

All alert types
0.39 USD -0.04 (-10.18%)

Regular-session close

0.42 +0.03 +6.71%

After hours · Nov 16, 4:36 PM ET

0.3823 Day range 0.49
0.3823 52-week range 4.34
YTD
-87.16%
1 year
-88.49%
Market cap
5.81M
EPS (ttm)
-1.63
Shares out
10.78M
Forward P/E
-1.50
YTD return
-87.16%
1-year return
-88.49%
50-day average
3.41
200-day average
4.86
Volume
188.53K
Avg volume
246.43K
Open
0.4316
Previous close
0.4331
Day's range
0.3823 – 0.49
52-week range
0.3823 – 4.34
Beta
1.57
Price target
20.50 (+5169.9%)

 

No chart data for this range yet.

Key statistics

Enterprise value
3.77M
Price / book
0.79
Free cash flow
-8.71M
Total cash
33.26M
Total debt
218.70K
Return on equity
-44.82%
Short % of float
1.87%

Fundamental scorecard

4 of 25 checks passed on LTRN’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
LTRN Revenue — quarterly 0
LTRN Net income — quarterly -7.07M
LTRN EPS — quarterly -0.57

Earnings

LTRN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.56-0.42+0.14+25.00%
Aug 8, 2024Jun 1, 2024-0.55-0.46+0.09+16.36%
Aug 8, 2024Jun 1, 2024-0.55———
May 9, 2024Mar 1, 2024-0.43———
May 9, 2024Mar 1, 2024-0.43-0.51-0.08-18.60%
Mar 18, 2024Dec 1, 2023-0.40———

Upgrades / downgrades

LTRN analyst upgrades and downgrades
DateFirmActionFromTo
Apr 25, 2024HC Wainwright & Co.reit—Neutral
Aug 10, 2023EF HuttonreitBuyBuy
Jun 26, 2023EF HuttonmainBuyBuy
May 18, 2023HC Wainwright & Co.init—Neutral
Mar 21, 2023EF Huttonreit—Buy
Feb 15, 2023EF Huttonmain—Buy

About Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on LTRN — it syncs with the Stock Master app.

Insider holders

LTRN insider holders
InsiderRelationLatest transactionDateShares held
FLETCHER AARON G.L.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJan 16, 20240
KEYSER DONALD JEFFREY PH.DDirectorConversion of Exercise of derivative securityJul 23, 20240
KREIS LESLIE W JRBeneficial Owner of more than 10% of a Class of SecuritySaleMay 23, 20240

Institution ownership

LTRN institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc3.37%363,7201.10MSep 29, 2024
CM Management, LLC1.72%185,000558.70KSep 29, 2024
NewEdge Advisors, LLC1.27%137,338414.76KSep 29, 2024
Geode Capital Management, LLC0.81%87,435264.05KSep 29, 2024
Renaissance Technologies, LLC0.78%84,000253.68KSep 29, 2024
Davenport & Co LLC0.50%53,814162.52KSep 29, 2024

Fund ownership

LTRN fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.37%256,113773.46KSep 29, 2024
Vanguard Extended Market Index Fund0.92%99,265299.78KSep 29, 2024
Fidelity Extended Market Index Fund0.43%46,104139.23KOct 30, 2024
Listed Funds Tr-Horizon Kinetics Medical ETF0.26%27,58283.30KSep 29, 2024
iShares Micro Cap ETF0.16%16,78250.68KOct 30, 2024
Fidelity Total Market Index Fund0.14%15,44046.63KOct 30, 2024